Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents, or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

The Urinary Incontinence drugs in development market research report provide comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.

Key Targets in the Urinary Incontinence Pipeline Products Market

The key targets in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic, Synaptosomal Associated Protein 25, 5-Hydroxytryptamine Receptor 2C, 5-Hydroxytryptamine Receptor 3, G Protein Coupled Receptor, Muscarinic Acetylcholine Receptor M1, Muscarinic Acetylcholine Receptor M2, Muscarinic Acetylcholine Receptor M3, and Sodium Dependent Noradrenaline Transporter.

Urinary Incontinence Pipeline Products Analysis Market by Targets

Urinary Incontinence Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Urinary Incontinence Pipeline Products Market

The key mechanisms of action in the Urinary Incontinence pipeline products market are Cholinergic Receptor Muscarinic Antagonist, Synaptosomal Associated Protein 25 Inhibitor, 5-Hydroxytryptamine Receptor 2C Agonist, 5-Hydroxytryptamine Receptor 3 Antagonist, G Protein Coupled Receptor Modulator, Muscarinic Acetylcholine Receptor M1 Antagonist, Muscarinic Acetylcholine Receptor M2 Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, and Sodium Dependent Noradrenaline Transporter Inhibitor.

Urinary Incontinence Pipeline Products Market Analysis by Mechanism of Actions

Urinary Incontinence Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Urinary Incontinence Pipeline Products Market

The key routes of administration in the Urinary Incontinence pipeline products market are intramuscular, parenteral, oral, intradermal, intravesical, subcutaneous, inhalational, intraarticular, intracavernous, intraprostatic, and transdermal.

Urinary Incontinence Pipeline Products Market Analysis by Routes of Administration

Urinary Incontinence Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Urinary Incontinence Pipeline Products Market

The key molecule types in the Urinary Incontinence pipeline products market are small molecule, cell therapy, biologic, protein, gene therapy, and oligonucleotide.

Urinary Incontinence Pipeline Products Market Analysis by Molecule Type

Urinary Incontinence Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Urinary Incontinence Pipeline Products Market

Some of the major companies in the Urinary Incontinence pipeline products market are Cook MyoSite Inc, Innovacell Biotechnologie AG, AbbVie Inc, Crystec Ltd, Exopharm Ltd, Ixaltis, Johnson & Johnson, MUVON Therapeutics AG, Ningbo Xijian Pharmaceutical Technology Co Ltd, and Orgenesis Inc.

Urinary Incontinence Pipeline Products Market Analysis by Companies

Urinary Incontinence Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Cholinergic Receptor Muscarinic, Synaptosomal Associated Protein 25, 5-Hydroxytryptamine Receptor 2C, 5-Hydroxytryptamine Receptor 3, G Protein Coupled Receptor, Muscarinic Acetylcholine Receptor M1, Muscarinic Acetylcholine Receptor M2, Muscarinic Acetylcholine Receptor M3, and Sodium Dependent Noradrenaline Transporter
Key mechanism of action Cholinergic Receptor Muscarinic Antagonist, Synaptosomal Associated Protein 25 Inhibitor, 5-Hydroxytryptamine Receptor 2C Agonist, 5-Hydroxytryptamine Receptor 3 Antagonist, G Protein Coupled Receptor Modulator, Muscarinic Acetylcholine Receptor M1 Antagonist, Muscarinic Acetylcholine Receptor M2 Antagonist, Muscarinic Acetylcholine Receptor M3 Antagonist, and Sodium Dependent Noradrenaline Transporter Inhibitor
Key routes of administration Intramuscular, Parenteral, Oral, Intradermal, Intravesical, Subcutaneous, Inhalational, Intraarticular, Intracavernous, Intraprostatic, and Transdermal
Key molecule type Small Molecule, Cell Therapy, Biologic, Protein, Gene Therapy, and Oligonucleotide
Major companies Cook MyoSite Inc, Innovacell Biotechnologie AG, AbbVie Inc, Crystec Ltd, Exopharm Ltd, Ixaltis, Johnson & Johnson, MUVON Therapeutics AG, Ningbo Xijian Pharmaceutical Technology Co Ltd, and Orgenesis Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Cook MyoSite Inc
Crystec Ltd
Exopharm Ltd
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
MUVON Therapeutics AG
Ningbo Xijian Pharmaceutical Technology Co Ltd
Orgenesis Inc
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
RION Health Inc
Saniona AB
Sinsin Pharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
Urovant Sciences Inc
Versameb AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Urinary Incontinence – Overview

Urinary Incontinence – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Urinary Incontinence – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Urinary Incontinence – Companies Involved in Therapeutics Development

AbbVie Inc

Cook MyoSite Inc

Crystec Ltd

Exopharm Ltd

Innovacell Biotechnologie AG

Ixaltis

Johnson & Johnson

MUVON Therapeutics AG

Ningbo Xijian Pharmaceutical Technology Co Ltd

Orgenesis Inc

Outpost Medicine Ltd

Pfizer Inc

Profem GmbH

Revance Therapeutics Inc

RION Health Inc

Saniona AB

Sinsin Pharmaceutical Co Ltd

Taiho Pharmaceutical Co Ltd

Urovant Sciences Inc

Versameb AG

Urinary Incontinence – Drug Profiles

Biologic for Stress Urinary Incontinence – Drug Profile

Product Description

Mechanism Of Action

Cell Therapy for Stress Urinary Incontinence – Drug Profile

Product Description

Mechanism Of Action

Cell Therapy for Urinary Incontinence – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Therapy for Urinary Stress Incontinence – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cevaris – Drug Profile

Product Description

Mechanism Of Action

History of Events

EG-017 – Drug Profile

Product Description

Mechanism Of Action

ICES-13 – Drug Profile

Product Description

Mechanism Of Action

History of Events

iltamiocel – Drug Profile

Product Description

Mechanism Of Action

History of Events

litoxetine – Drug Profile

Product Description

Mechanism Of Action

History of Events

onabotulinumtoxin A – Drug Profile

Product Description

Mechanism Of Action

History of Events

onabotulinumtoxinA biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

OP-352 – Drug Profile

Product Description

Mechanism Of Action

History of Events

oxybutynin – Drug Profile

Product Description

Mechanism Of Action

Prof-003 – Drug Profile

Product Description

Mechanism Of Action

pVAX-hSlo – Drug Profile

Product Description

Mechanism Of Action

History of Events

Rev-md – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize 5-HT2C for Urinary Incontinence – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence – Drug Profile

Product Description

Mechanism Of Action

TAS-303 – Drug Profile

Product Description

Mechanism Of Action

History of Events

tolterodine – Drug Profile

Product Description

Mechanism Of Action

trospium chloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

VMB-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Urinary Incontinence – Dormant Projects

Urinary Incontinence – Discontinued Products

Urinary Incontinence – Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

Feb 17, 2022: Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

Nov 04, 2021: Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference

Dec 17, 2020: FDA grants RMAT designation for Cook MyoSite’s investigational autologous Muscle Derived Cells for Urinary Sphincter Repair

Jan 11, 2018: Sleep quality improves with help of incontinence drug

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting

Oct 09, 2013: Allergan’s BOTOX (Botulinum Toxin Type A) Recommended by the Scottish Medicines Consortium for the Management of Detrusor Overactivity with Urinary Incontinence (Leakage) in Patients with Multiple Sclerosis or Spinal Cord Injury

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg

Sep 27, 2012: Allergan’s Botox Receives UK Authorization For Urinary Leakage In Patients With Multiple Sclerosis Or Spinal Cord Injury

Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference

Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency

Aug 30, 2011: Innovacell passes a further milestone

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Urinary Incontinence, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Urinary Incontinence – Pipeline by AbbVie Inc, 2022

Urinary Incontinence – Pipeline by Cook MyoSite Inc, 2022

Urinary Incontinence – Pipeline by Crystec Ltd, 2022

Urinary Incontinence – Pipeline by Exopharm Ltd, 2022

Urinary Incontinence – Pipeline by Innovacell Biotechnologie AG, 2022

Urinary Incontinence – Pipeline by Ixaltis, 2022

Urinary Incontinence – Pipeline by Johnson & Johnson, 2022

Urinary Incontinence – Pipeline by MUVON Therapeutics AG, 2022

Urinary Incontinence – Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2022

Urinary Incontinence – Pipeline by Orgenesis Inc, 2022

Urinary Incontinence – Pipeline by Outpost Medicine Ltd, 2022

Urinary Incontinence – Pipeline by Pfizer Inc, 2022

Urinary Incontinence – Pipeline by Profem GmbH, 2022

Urinary Incontinence – Pipeline by Revance Therapeutics Inc, 2022

Urinary Incontinence – Pipeline by RION Health Inc, 2022

Urinary Incontinence – Pipeline by Saniona AB, 2022

Urinary Incontinence – Pipeline by Sinsin Pharmaceutical Co Ltd, 2022

Urinary Incontinence – Pipeline by Taiho Pharmaceutical Co Ltd, 2022

Urinary Incontinence – Pipeline by Urovant Sciences Inc, 2022

Urinary Incontinence – Pipeline by Versameb AG, 2022

Urinary Incontinence – Dormant Projects, 2022

Urinary Incontinence – Dormant Projects, 2022 (Contd..1)

Urinary Incontinence – Dormant Projects, 2022 (Contd..2)

Urinary Incontinence – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Urinary Incontinence, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.